The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
IKZF1 (Ikaros) Deletions in BCR-ABL1 –Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report
Abstract
Purpose: The causes of the aggressive nature of BCR-ABL1–positive adult acute lymphoblastic leukemia (ALL) are unknown. To identify, at the submicroscopic level, oncogenic lesions that cooperate with BCR-ABL1 to induce ALL, we performed an investigation of genomic copy number alterations using single nucleotide polymorphism array, genomic polymerase chain reaction, and sequencing of candidate genes. Patients and Methods: Eighty-three patients with de novo adult Philadelphia chromosome (Ph) –positive ALL were enrolled onto institutional (n = 17) or Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Working Party delle Leucemia Acute (n = 66) clinical trials. Treatments included tyrosine kinase inhibitor (TKI) alone, conventional chemotherapy, or a combination of TKI and chemotherapy. Results: A 7p12 deletion of IKZF1 (Ikaros) was identified in 52 (63%) of 83 patients. The pattern of deletion varied among different patients, but the two most common deletion types were loss of exons 4 to 7 in 31 (37%) of 83 patients and loss of exons 2 to 7 in 17 (20%) of 83 patients. Disease-free survival (DFS) was shorter in patients with IKZF1 deletion versus patients with IKZF1 wild type (10 v 32 months, respectively; P = .02). Furthermore, a significantly shorter cumulative incidence of relapse was recorded in patients with IKZF1 deletion versus patients with IKZF1 wild type (10.1 v 56.1 months, respectively; P = .001). Multivariate analysis confirmed the negative prognostic impact of IKZF1 deletion on DFS (P = .04). Conclusion: We conclude that IKZF1 deletions are likely to be a genomic alteration that significantly affects the prognosis of Ph-positive ALL in adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
GROFFEN, J., STEPHENSON, J., HEISTERKAMP, N., DEKLEIN, A., BARTRAM, C., & GROSVELD, G. (1984) · Cell · doi:10.1016/0092-8674(84)90077-1 · Cited by 1,599
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422 · cited 9×
“We correlated focal IKZF1 deletions with the clinical outcome, OS, cumulative incidence of relapse (CIR), relapse rate after obtaining a CHR, and DFS and demonstrated that Ikaros deletions represent the most important genetic prognostic factor thus far described in Phpositive ALL.”
BackgroundInfluentialBCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072
Chromosome Studies on Normal and Leukemic Human Leukocytes
(1960) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/25.1.85 · Cited by 1,069
The ikaros gene is required for the development of all lymphoid lineages
Georgopoulos, K., Bigby, M., Wang, J.-H., Molnar, A., Wu, P., Winandy, S., & Sharpe, A. (1994) · Cell · doi:10.1016/0092-8674(94)90407-3 · Cited by 985
Ha, S., Karhi, K. K., Rayter, S., Heisterkamp, N., Eridani, S., Powle, R., Lawler, S. D., Groffen, J., Foulkes, J. G., Greaves, M. F., et al. (1987) · Nature · doi:10.1038/325635a0 · Cited by 434
Vignetti, M., Fazi, P., Cimino, G., Martinelli, G., Di Raimondo, F., Ferrara, F., Meloni, G., Ambrosetti, A., Quarta, G., Pagano, L., et al. (2007) · Blood · doi:10.1182/blood-2006-10-052746 · Cited by 374
Self-citationOttmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R. A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A. M., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073528 · Cited by 366
Self-citationUnique Forms of the abl Tyrosine Kinase Distinguish Ph 1 -Positive CML from Ph 1 -Positive ALL
Clark, S. S., McLaughlin, J., Crist, W. M., Champlin, R., & Witte, O. N. (1987) · Science · doi:10.1126/science.3541203 · Cited by 320
le Coutre, P., Ottmann, O. G., Giles, F., Kim, D.-W., Cortes, J., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O'Brien, S. G., et al. (2008) · Blood · doi:10.1182/blood-2007-04-083196 · Cited by 294
Self-citationIacobucci, I., Storlazzi, C. T., Cilloni, D., Lonetti, A., Ottaviani, E., Soverini, S., Astolfi, A., Chiaretti, S., Vitale, A., Messa, F., et al. (2009) · Blood · doi:10.1182/blood-2008-08-173963 · Cited by 222
Self-citationThe biology and therapy of adult acute lymphoblastic leukemia
Faderl, S., Jeha, S., & Kantarjian, H. M. (2003) · Cancer · doi:10.1002/cncr.11664 · Cited by 193
Molnár, A., Wu, P., Largespada, D. A., Vortkamp, A., Scherer, S., Copeland, N. G., Jenkins, N. A., Bruns, G., & Georgopoulos, K. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.2.585 · Cited by 167
Control of lymphocyte development by the Ikaros gene family
Cortes, M., Wong, E., Koipally, J., & Georgopoulos, K. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)80028-4 · Cited by 158
Phosphorylation Controls Ikaros's Ability To Negatively Regulate the G1-S Transition
Arco, P. G., Maki, K., & Georgopoulos, K. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2797-2807.2004 · Cited by 117
Iacobucci, I., Lonetti, A., Messa, F., Cilloni, D., Arruga, F., Ottaviani, E., Paolini, S., Papayannidis, C., Piccaluga, P. P., Giannoulia, P., et al. (2008) · Blood · doi:10.1182/blood-2007-09-112631 · Cited by 111
Self-citationPane, F., Cimino, G. G., Izzo, B., Camera, A., Vitale, A., Quintarelli, C., Picardi, M., Specchia, G., Mancini, M., Cuneo, A., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403683 · Cited by 97
Self-citationPiccaluga, P. P., Paolini, S., & Martinelli, G. (2007) · Cancer · doi:10.1002/cncr.22881 · Cited by 93
Self-citationDual tyrosine kinase inhibitors in chronic myeloid leukemia
Martinelli, G., Soverini, S., Rosti, G., & Baccarani, M. (2005) · Leukemia · doi:10.1038/sj.leu.2403950 · Cited by 68
Self-citationA complex network of regulatory elements in Ikaros and their activity during hemo‐lymphopoiesis
Kaufmann, C., Yoshida, T., Perotti, E., Landhuis, E., Wu, P., & Georgopoulos, K. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg186 · Cited by 47
Iacobucci, I., Lonetti, A., Cilloni, D., Messa, F., Ferrari, A., Zuntini, R., Ferrari, S., Ottaviani, E., Arruga, F., Paolini, S., et al. (2008) · Haematologica · doi:10.3324/haematol.13260 · Cited by 36
Self-citationIkaros: a key regulator of haematopoiesis
Westman, B. J., Mackay, J. P., & Gell, D. A. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00070-5 · Cited by 32
Hematopoiesis flies high with Ikaros
Smale, S. T., & Dorshkind, K. A. (2006) · Nature Immunology · doi:10.1038/ni0406-367 · Cited by 9
Cited by
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 714
Genetic Basis of Acute Lymphoblastic Leukemia
Iacobucci, I., & Mullighan, C. G. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7836 · Cited by 556
Self-citationPediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Pui, C.-H., Mullighan, C. G., Evans, W. E., & Relling, M. V. (2012) · Blood · doi:10.1182/blood-2012-05-378943 · Cited by 500
Hoelzer, D., Bassan, R., Dombret, H., Fielding, A., Ribera, J. M., & Buske, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw025 · Cited by 463
Metadata
- Authors
- Martinelli, G., Iacobucci, I., Storlazzi, C. T., Vignetti, M., Paoloni, F., Cilloni, D., Soverini, S., Vitale, A., Chiaretti, S., Cimino, G., Papayannidis, C., Paolini, S., Elia, L., Fazi, P., Meloni, G., Amadori, S., Saglio, G., Pane, F., Baccarani, M., & Foà, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-11-01
- Volume
- 27
- Issue
- 31
- Pages
- 5202-5207
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2136334823
- Cited by
- 317
- References
- 26
- FWCI
- 21.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.